HOGAN MARK D

Director Mark D. Hogan buys 5,000 BCBP shares at $7.97; prior 5 BCBP buys all showed positive 90-day returns

Director Mark D. Hogan purchased 5,000 shares of BCB Bancorp at $7.97 on 2026-02-27, bringing his holdings to 103,352 shares. This open-market buy occurs at a price 20.4% below the 52-week high of $10.17, and follows a consistent pattern: across his prior 5 trades at BCBP, all 5 buys generated positive 90-day returns, ranging from +6.4% to +23.7%, indicating reliable timing accuracy at this specific ticker. His cross-ticker track record shows a 93.33% 90-day win rate across 15 prior buys with an average 90-day return of +14.0%, establishing a strong historical precedent for this insider's buy discipline. With a current P/E of 50.62 and net income of $4,262,000.00, BCBP trades at an elevated multiple, yet the insider's repeated accumulation at depressed price points suggests conviction in the company's intermediate-term prospects despite current valuation constraints.

Director Hogan buys 10,000 shares of BCBP at $7.74; price now down -42.8% from 52-week high of $13.55, cluster of 3 insiders buying in 14 days.

Director Mark D. Hogan purchased 10,000 shares at $7.74 on 2025-06-13, increasing his holdings to 621,140 shares. The stock is currently trading at $7.75, down -42.8% from its 52-week high of $13.55 and -21.2% over the past 90 days. His prior trades at BCBP show strong timing: 4 of 4 measurable buys were well-timed at the 90-day mark, with returns ranging from +20.9% to +30.7%, and his cross-ticker track record shows 92.31% 90-day win rate across 14 prior buys averaging +14.6% 90-day return. The transaction is part of a cluster pattern with 2 other insiders also buying within the past 14 days. However, the company's fundamentals show a net loss of $-8,324,000.00 and a P/E of 29.81 at a market cap of $133,010,359.25, creating a tension between insider accumulation and deteriorating earnings.

Director Mark Hogan buys 10,000 BCBP shares at $8.04; timing consistent with his prior 4 well-timed buys, despite -39.7% from 52-week high.

Director Mark Hogan purchased 10,000 shares at $8.04, increasing his holdings by 11.3% to 98,352 shares. His prior five trades at BCBP show a strong timing pattern: four of those five buys achieved positive 90-day returns (20.9%, 23.7%, 23.5%, 30.7%), with only one purchase (2023-06-09) turning negative over 90 days. This current acquisition repeats that pattern at a price 39.7% below the 52-week high and while the stock is down 19.3% over 90 days, aligning with the company's reported net loss of $8.3M. The cross-ticker track record of 92.31% 90-day win rate on 13 prior buys suggests precision in entry timing, but the company's negative earnings environment and depressed valuation relative to historical levels warrant careful observation of whether this transaction precedes recovery or marks exposure to ongoing fundamental weakness.